News
Five9, Inc. (NASDAQ: FIVN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims, Over $8 Million Insider Sales " Schubert Jonckheer & Kolbe
46+ min ago (115+ words) Schubert Jonckheer & Kolbe LLP advises Five9, Inc. (NASDAQ: FIVN) investors that the firm is investigating potential legal claims arising from alleged false statements about the company's projected revenue growth and macroeconomic conditions affecting sales. Current shareholders are encouraged to contact the…...
Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof; Notice of a Commission Determination Not To Review an Initial Determination Amending the Complaint and Notice of Investigation
5+ hour, 49+ min ago (316+ words) A Notice by the International Trade Commission on 05/19/2026 This PDF is FR Doc. 2026-10010 as it appeared on Public Inspection on 05/18/2026 at 8: 45 am. On September 12, 2025, the Commission determined not to review Order No. 15 granting Complainant's motion to amend the complainant and…...
Securities Fraud Investigation Into Black Rock Coffee Bar, Inc. (BRCB) Announced " Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
6+ hour, 5+ min ago (188+ words) Securities Fraud Investigation Into Black Rock Coffee Bar, Inc The National Law Review Securities Fraud Investigation Into Black Rock Coffee Bar, Inc. (BRCB) Announced " Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS…...
UPDATE 4-Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds
1+ hour, 53+ min ago (609+ words) Devdiscourse UPDATE 4-Takeda engaged in antitrust scheme to delay generic constipation drug, US jury finds Federal antitrust law that covers the bulk of the plaintiffs' claims allows damages to be automatically tripled, meaning $821. 7 million of the jury's award could swell…...
Japan's Takeda engaged in antitrust scheme to delay generic constipation drug
3+ hour, 14+ min ago (339+ words) A U. S. jury on Monday found Japan-based Takeda Pharmaceutical 4502. T liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an anticompetitive scheme....
Webinar: What Practitioners and Facilities Need to Know About Navigating the Multi Plan Litigation
8+ hour, 30+ min ago (244+ words) When: June 23, 6 pm CT Register today: Zoom link The session will conclude with a Q&A, and open discussion is welcome and appreciated. All participant information will be kept private. The court also has appointed attorneys to litigate a proposed…...
Takeda Liable In IBS Drug Pay-For-Delay Trial
10+ hour, 36+ min ago (63+ words) Law360 Try our Advanced Search for more refined results The Practice of Law Deep News & Analysis Law360 | The Practice of Law Law360 Authority | Deep News & Analysis Law360 Pulse | The Business of Law Takeda Liable In IBS Drug Pay-For-Delay Trial Law360 is on it, so you…...
Aetna Denied A Freeze On Trans Facial Surgery Order - Law360 Healthcare Authority
7+ hour, 51+ min ago (86+ words) Aetna Denied A Freeze On Trans Facial Surgery Order Law360 Law360 | The Practice of Law Law360 Authority | Deep News & Analysis Law360 Pulse | The Business of Law Aetna Denied A Freeze On Trans Facial Surgery Order By Kellie Mejdrich " May 18, 2026, 5: 58 PM EDT /healthcare-authority/tracked_cases? case_id=66e0561c7622650c23937be6&case_title=Gordon+et…...
BW Investors Have Opportunity to Lead Babcock & Wilcox Enterprises, Inc. Securities Fraud Lawsuit
2+ hour, 27+ min ago (528+ words) Weekly Voice The Largest South Asian News Platforms since 1997 NEW YORK, May 18, 2026 /PRNewswire/ " Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (B&W) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive…...
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit
1+ hour, 43+ min ago (438+ words) Weekly Voice The Largest South Asian News Platforms since 1997 NEW YORK, May 18, 2026 /PRNewswire/ " Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gossamer Bio, Inc. (NASDAQ: GOSS) between June 16, 2025 and February 20, 2026, inclusive (the "Class…...